Mesenas Steven J
Department of Gastroenterology, Singapore General Hospital, Singapore.
Ann Acad Med Singap. 2006 Feb;35(2):89-95.
Endoscopic retrograde cholangiopancreatography (ERCP) has been the premier diagnostic and therapeutic endoscopic procedure in the management of pancreatic and biliary diseases (PBD). The use of endoscopic ultrasound (EUS), including EUS-guided fine needle aspiration (FNA), of pancreatic and biliary tumours has become more widely available in the last decade and has gradually replaced diagnostic ERCP. Together with EUS, other imaging modalities like magnetic resonance cholangiopancreatography (MRCP) have resulted in a decrease in the number of ERCPs. With the advent of interventional EUS, ERCP is at risk of being completely eclipsed.
A search of all relevant articles on EUS and ERCP from Medline and peer-reviewed journals.
This review article examines the exact place of ERCP and EUS and their relative contributions in the management algorithm of PBD.
Although diagnostic EUS, including EUS-guided FNA, is well established in the evaluation of PBD, interventional EUS is still in its infancy and its true potential is unknown. Therefore, therapeutic ERCP still has a vital, albeit smaller role to play in the treatment of pancreatic and biliary diseases.
内镜逆行胰胆管造影术(ERCP)一直是胰腺和胆道疾病(PBD)管理中首要的诊断和治疗性内镜检查程序。在过去十年中,包括内镜超声引导下细针穿刺活检(EUS-FNA)在内的胰腺和胆管肿瘤的内镜超声(EUS)应用已变得更为广泛,并且逐渐取代了诊断性ERCP。与EUS一起,其他成像方式如磁共振胰胆管造影(MRCP)已导致ERCP的数量减少。随着介入性EUS的出现,ERCP有被完全取代的风险。
检索Medline和同行评审期刊上所有关于EUS和ERCP的相关文章。
这篇综述文章探讨了ERCP和EUS的确切地位及其在PBD管理算法中的相对贡献。
尽管包括EUS-FNA在内的诊断性EUS在PBD评估中已得到充分确立,但介入性EUS仍处于起步阶段,其真正潜力尚不清楚。因此,治疗性ERCP在胰腺和胆道疾病的治疗中仍发挥着至关重要但相对较小的作用。